SB-1317

Modify Date: 2024-01-13 11:30:04

SB-1317 structure	Common Name	SB-1317
	CAS Number	1204918-72-8	Molecular Weight	372.46
	Density	1.1±0.1 g/cm3	Boiling Point	577.1±60.0 °C at 760 mmHg
	Molecular Formula	C₂₃H₂₄N₄O	Melting Point	N/A
	MSDS	N/A	Flash Point	302.8±32.9 °C

Use of SB-1317

Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma[1][2].

Name	(16E)-14-Methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(27),3,5,8(26),9,11,16,21,23-decaene
Synonym	More Synonyms

Description	Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> JAK Signaling Pathways >> Epigenetics >> JAK Signaling Pathways >> Stem Cell/Wnt >> JAK Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FLT3 Signaling Pathways >> Cell Cycle/DNA Damage >> CDK
References	[1]. William AD, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem. 2012 Jan 12;55(1):169-96. [2]. Pasha MK, et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> JAK

Signaling Pathways >> Epigenetics >> JAK

Signaling Pathways >> Stem Cell/Wnt >> JAK

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FLT3

Signaling Pathways >> Cell Cycle/DNA Damage >> CDK

References

[1]. William AD, et al. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer. J Med Chem. 2012 Jan 12;55(1):169-96.

[2]. Pasha MK, et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.

Density	1.1±0.1 g/cm3
Boiling Point	577.1±60.0 °C at 760 mmHg
Molecular Formula	C₂₃H₂₄N₄O
Molecular Weight	372.46
Flash Point	302.8±32.9 °C
Exact Mass	372.195007
LogP	4.76
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.577

(16E)-14-Methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.1.1]heptacosa-1(25),2(27),3,5,8(26),9,11,16,21,23-decaene

20-Oxa-5,7,14,27-tetraazatetracyclo[19.3.1.1.1]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-methyl-, (16E)-

SB-1317

DC Chemicals Limited
China
Product Name: SB-1317
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Get all suppliers and price by the below link:

SB-1317 suppliers

SB-1317 price

SB-1317

Use of SB-1317

Names

SB-1317 Biological Activity

Chemical & Physical Properties

Synonyms